. home.aspx



AZ Calquence granted US Breakthrough Therapy Designation

August 14, 2019 / Anna Smith

AstraZeneca has announced that Calquence acalabrutinib has been granted US Breakthrough Therapy Designation BTD for chronic lymphocytic leukaemia. The US Food and Drug Administration FDA granted the designation as a monotherapy treatment for adult patients with the disease, based on positive results from the interim analyses of the ELEVATE-TN and ASCEND Phase III clinical trials, which will serve as the foundation for regulatory submissions later this year. Together the trials showed that Calquence alone or in combination significantly increased the time patients lived without disease progression or death, with safety and tolerability that was consistent with its established profile. An FDA BTD is designed to accelerate the development and regulatory review of new medicines that are intended to treat a serious condition and that have shown encouraging early clinical results which may demonstrate substantial improvement on a clinically-significant endpoint over currently-available medic...